Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rare stroke causes no longer overlooked: new italian network aims to diagnose and understand mysterious brain diseases

NCT ID NCT06935578

Knowledge-focused Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 02, 2026 · Updated 2 times

Summary

This study is creating a large network of hospitals across Italy to improve the diagnosis and understanding of rare cerebrovascular diseases (rCVDs), such as CADASIL, Fabry disease, and Moyamoya. Researchers will collect medical information and blood samples from 500 patients to describe the diseases' features and find biological markers. The goal is to help doctors recognize these conditions more easily and reduce the number of strokes with unknown cause.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

500 people

The number who actually took part.

Started

May 2023

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults, male and female patients affected by a Rare Cerebrovascular Disease (rCVD)

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients with a clinical, genetic and/or neuroradiological diagnosis of rCVD (CADASIL, Fabry's disease, COL4A1, Sneddon's syndrome or Moyamoya arteriopathy), who have had at least one brain MRI study; Exclusion Criteria: * na

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cadasil are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cerebral arteriopathy with subcortical infarcts and leukoencephalopathy cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 COL4A1-related disorder COL4A1/A2-related disorder disease Fabry disease Moyamoya disease Sneddon syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cadasil Cadasil (diagnosis) COL4A1\2 Fabry disease Moya moya disease Moyamoya Moyamoya syndrome Sneddon syndrome

Contacts and locations

Locations

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, Italy

  • ASST Melegnano Martesana

    Melegnano, MI, Italy

  • ASST di Cremona

    Cremona, Italy

  • Fondazione IRCCS Istituto Neurologico Carlo Besta

    Milan, Italy

  • Fondazione Istituto G. Giglio, Cefalù

    Cefalù, PA, Italy

  • IRCCS Policlinico San Matteo, Pavia

    Pavia, Italy

  • Neurologia PO Levante Asl 2 Savonese

    Savona, Italy

  • Neurologia Stroke Unit dell'Asst Rhodense

    Rho, Mi, Italy

  • Neurologia d'Urgenza e Stroke Unit dell'Ospedale di Pescara

    Pescara, Italy

  • Neurologia dell'Ospedale Sandro Pertini - ASL Roma2

    Roma, Italy

  • Ospedale "Spaziani" di Frosinone

    Frosinone, Italy

  • Ospedale Luigi Sacco, ASST Fatebenefratelli Sacco

    Milan, Italy

  • Ospedale Regionale Generale "F. Miulli", Acquaviva delle Fonti

    Acquaviva delle Fonti, BA, Italy

  • Policlinico Tor Vergata, UOSD Stroke Unit

    Roma, Italy

  • Stroke Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano

    Milan, Italy

  • U.O. Neurologia, Ospedale Sant'Andrea, La Spezia

    La Spezia, Italy

  • UO Neurologia degli Ospedali di Cesena e Forlì, Ospedale Bufalini Cesena ed Ospedale Morgagni-Pierantoni (Ausl della Romagna)

    Cesena, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.